Semaglutide
A synthetic GLP-1 analog, marketed as Ozempic (diabetes) and Wegovy (obesity). It reduces appetite and body weight by an average of 15-17% in clinical trials. It has also shown a 20% reduction in cardiovascular risk in the SELECT trial.
A synthetic GLP-1 analog, marketed as Ozempic (diabetes) and Wegovy (obesity). It reduces appetite and body weight by an average of 15-17% in clinical trials. It has also shown a 20% reduction in cardiovascular risk in the SELECT trial.